A Billion Base Pairs, Times Two

Both the public Human Genome Project and the private Celera Genomics-sponsored effort announced within a month of each other that they have sequenced a billion base pairs--about a third of human's total genetic code. Despite those twin landmarks, it's still difficult to say which project is ahead of the other in the quest to finish a "rough draft," or 90 percent completed copy, by spring 2000. This handicappers' confusion (in a competition both teams have said is not a race1) can be attributed

Written byPaul Smaglik
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Both the public Human Genome Project and the private Celera Genomics-sponsored effort announced within a month of each other that they have sequenced a billion base pairs--about a third of human's total genetic code. Despite those twin landmarks, it's still difficult to say which project is ahead of the other in the quest to finish a "rough draft," or 90 percent completed copy, by spring 2000.

This handicappers' confusion (in a competition both teams have said is not a race1) can be attributed to the different sequencing strategies each effort employs. Publicly funded sequencers are putting finished clones on a map as they go, while the Rockville, Md.-based Celera is first sequencing each into different-size fragments, then matching overlapped areas against each other to form a coherent picture--sort of a biological jigsaw puzzle of unprecedented scope.

Celera first announced its achievement in an Oct. 20 news release; the Human Genome ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies